Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Regulatory T cells (Tregs) are critical mediators of immune homeostasis and hold significant promise in the quest for transplantation tolerance. Progress has now reached a critical threshold as techniques for production of clinical therapies are optimised and Phase I/II clinical trials are in full swing. Initial safety and efficacy data are being reported, with trials assessing a number of different strategies for the introduction of Treg therapy. It is now more crucial than ever to elucidate further the function and behaviour of Tregsin vivoand ensure safe delivery. This review will discuss the current state of the art and future directions in Treg therapy.

Original publication

DOI

10.1016/j.humimm.2017.12.013

Type

Journal article

Journal

Hum Immunol

Publication Date

27/12/2017

Keywords

Humanized mouse, Immunosuppression, Regulatory T cells, T cell, Tolerance